A Strategy for Rational Design of Fully Synthetic Glycopeptide Conjugate Vaccines
Overview
Affiliations
The present study describes a strategy to rationally design fully synthetic glycopeptide conjugate vaccines. Glycopeptide immunogens were constructed by coupling synthetic oligosaccharides comprising repeating units of synthetic 3-beta-D-ribose-(1-1)-D-ribitol-5-phosphate (sPRP) to synthetic peptides containing potent T-helper cell determinants and B-cell epitopes of the Haemophilus influenzae type b (Hib) outer membrane proteins (OMPs) P1, P2, and P6. Rabbit immunogenicity studies revealed that some of these fully synthetic glycoconjugates were capable of eliciting high titers of both anti-PRP and anti-OMP immunoglobulin G antibodies. In addition, we systematically investigated the factors which could influence their immunogenicity. We observed that the magnitude of the anti-PRP antibody response markedly depended on the relative spatial orientation of sPRP and T-cell epitopes, the anti-PRP antibody response was enhanced when a multiple antigenic peptide was used as a carrier, the anti-PRP antibody response was optimal for three PRP repeating units, and lipidation of peptide-PRP conjugates had a minimal effect on the magnitude of the anti-PRP antibody response. The results of this study clearly demonstrate that coupling a carbohydrate hapten to a peptide can provide T-cell help and convert it into a T-cell-dependent antigen. The antisera raised against these conjugates were also found to be protective against Hib infection in the infant rat model of bacteremia.
Nonne F, Iacono L, Bertuzzi S, Unione L, Proietti D, Norais N ACS Cent Sci. 2024; 10(5):978-987.
PMID: 38799664 PMC: 11117310. DOI: 10.1021/acscentsci.3c01515.
Micoli F, Stefanetti G, MacLennan C Front Mol Biosci. 2023; 10:1201693.
PMID: 37261327 PMC: 10227950. DOI: 10.3389/fmolb.2023.1201693.
Impact and Control of Sugar Size in Glycoconjugate Vaccines.
Stefanetti G, MacLennan C, Micoli F Molecules. 2022; 27(19).
PMID: 36234967 PMC: 9572008. DOI: 10.3390/molecules27196432.
Glycoconjugate Vaccines for Prevention of Type b Diseases.
Khatuntseva E, Nifantiev N Russ J Bioorg Chem. 2021; 47(1):26-52.
PMID: 33776394 PMC: 7980804. DOI: 10.1134/S1068162021010106.
Baek J, Geissner A, Rathwell D, Meierhofer D, Pereira C, Seeberger P Chem Sci. 2018; 9(5):1279-1288.
PMID: 29675174 PMC: 5887106. DOI: 10.1039/c7sc04521b.